Fundraising FoxVetmab Biosciences
San Diego, US · Founded 2022 · Delaware corporation
Find your way into Vetmab Biosciences
Sign up to see every warm intro you have to Vetmab Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Vetmab Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
VETmAb BIO is a veterinary biotechnology company developing monoclonal antibody (mAb) therapeutics for dogs and cats. It targets veterinarians treating companion animals, and its founding team previously built and sold KindredBio.
Founders & leadership
Vetmab Biosciences was founded in 2022 by Denise Bevers.
RC
Richard ChinCo-founder, Chair of the Board
HZ
Hangjun ZhanCo-founder, Chair of the Scientific Advisory Committee, Board Member
Board
NA
Neeraj AgrawalBoard director
CM
Chrysa MineoBoard director
Reported raises · per SEC filings
Form D private placements$14M disclosed across 4 rounds · 2022–2026
▶$11.4MraisedSep 2026 · 30 investors · BiotechnologyRule 506(b)
▶$11.4MraisedSep 2026 · 30 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Denise BeversExecutive Officer, Director
- Richard ChinExecutive Officer, Director
- Hangjun ZhanDirector
- Neeraj AgrawalDirector
- Chrysa MineoDirector
- Offering amount
- $11.9M
- Amount sold
- $11.4M
- First sale
- Sep 2026
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$575KraisedDec 2023 · 5 investors · BiotechnologyRule 506(b)
▶$575KraisedDec 2023 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Denise BeversExecutive Officer, Director
- Hangjun ZhanDirector
- Richard ChinExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $575K
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$2MraisedAug 2022 · 28 investors · BiotechnologyRule 506(b)
▶$2MraisedAug 2022 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Hangjun ZhanDirector
- Richard ChinExecutive Officer, Director
- Denise Marie BeversExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- Minimum investment
- $10K
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$22raisedJul 2022 · 42 investors · BiotechnologyRule 506(b)
▶$22raisedJul 2022 · 42 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard ChinDirector
- Hangjun ZhanDirector
- Denise Marie BeversExecutive Officer, Director
- Offering amount
- $22
- Amount sold
- $22
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Vetmab Biosciences do?
- VETmAb BIO is a veterinary biotechnology company developing monoclonal antibody (mAb) therapeutics for dogs and cats. It targets veterinarians treating companion animals, and its founding team previously built and sold KindredBio.
- Who founded Vetmab Biosciences?
- Vetmab Biosciences was founded by Denise Bevers in 2022.
- How much funding has Vetmab Biosciences raised?
- Vetmab Biosciences has disclosed $14M raised across 4 rounds.
- Where is Vetmab Biosciences headquartered?
- Vetmab Biosciences is headquartered in San Diego, US.